Home › Aimmune Therapeutics Announces Positive Phase 2 Study Results Of AR101 For The Treatment Of Peanut Allergy
 

Keywords :   


Aimmune Therapeutics Announces Positive Phase 2 Study Results Of AR101 For The Treatment Of Peanut Allergy

2015-06-17 06:39:17| foodingredientsonline Home Page

Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced recently that a Phase 2 study (ARC001) evaluating the company’s lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively

Tags: of results study positive

Category:Food and Related Products

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »